Scan­dal-prone Sub­sys mak­er In­sys falls as au­di­tor flags go­ing con­cern doubt

Af­ter hir­ing Lazard in the fourth quar­ter for coun­sel on cap­i­tal plan­ning and strate­gic al­ter­na­tives, the au­di­tor of the con­tro­ver­sial opi­oid painkiller mak­er In­sys Ther­a­peu­tics has raised doubts on the drug­mak­er’s abil­i­ty to con­tin­ue as a go­ing con­cern.

In­sys has a con­tentious past it is now pay­ing for in mil­lions with le­gal fees — its for­mer ex­ec­u­tives are em­broiled in court for al­leged­ly brib­ing doc­tors to pre­scribe its po­tent, ad­dic­tive fen­tanyl spray Sub­sys off-la­bel, by win­ing and din­ing them, pay­ing them to speak at “ed­u­ca­tion­al events” and in one case even a lap dance. Mean­while, the drug­mak­er’s bil­lion­aire founder and chief John Kapoor is on tri­al for rack­e­teer­ing and con­spir­a­cy as­so­ci­at­ed with Sub­sys sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER